The efficacy and tolerability of ultra-hypofractionated radiotherapy in low-intermediate risk prostate cancer patients: single center experience

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA A Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Mohler JL, Kantoff PW, Armstrong AJ, et al. Prostate cancer, version 2. J Natl Compr Canc Netw. 2014;12(5):686–718. 2014;
   PubMed Web of Science ®Google Scholar
• Mantz C. A phase II trial of stereotactic ablative body radiotherapy for low-risk prostate cancer using a non-robotic linear accelerator and real-time target tracking: report of toxicity, quality of life, and disease control outcomes with 5-year minimum follow-up. Front Oncol. 2014;4:279.
   PubMedGoogle Scholar
• Dasu A, Toma-Dasu I. Prostate alpha/beta revisited - an analysis of clinical results from 14 168 patients. Acta Oncol. 2012;51(8):963–974.
   PubMed Web of Science ®Google Scholar
• Miralbell R, Roberts SA, Zubizarreta E, et al. Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: α/β = 1.4 (0.9-2.2) Gy. Int J Radiat Oncol Biol Phys. 2012;82(1):e17–e24.
   PubMedGoogle Scholar
• King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol. 2011;43:428–437.
   PubMedGoogle Scholar
• Kishan AU, King CR. Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer. Semin Radiat Oncol. 2017;27(3):268–278.
   PubMed Web of Science ®Google Scholar
• Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: executive summary of an ASTRO, ASCO and AUA evidence-based guideline. J Urol. 2019;201(3):528–534.
   PubMed Web of Science ®Google Scholar
• Beckendorf V, Guerif S, Le PE, et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of Getug 06 randomized trial. Int J Radiat Oncol Biol Phys. 2011;80(4):1056–1063.
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Sydes MR, Graham JD, et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 2007;8(6):475–487.
   PubMed Web of Science ®Google Scholar
• Peeters STH, Heemsbergen WD, Koper PCM, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24(13):1990–1996.
   PubMed Web of Science ®Google Scholar
• Zietman AL, DeSilvio ML, Slater JD, et al. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA. 2005;294(10):1233–1239.
   PubMed Web of Science ®Google Scholar
• Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35(1):310–317.
   PubMed Web of Science ®Google Scholar
• Yu T, Zhang Q, Zheng T, et al. The effectiveness of ıntensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One. 2016;11(5):e0154499.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Levin EJ, Hunt M, et al. Incidence of late rectal and urinary toxicities after three‐dimensional conformal radiotherapy and intensity‐modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70(4):1124–1129.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55(3):241–249.
   PubMed Web of Science ®Google Scholar
• Lin YW, Lin KH, Ho HW, et al. Treatment plan comparison between stereotactic body radiation therapy techniques for prostate cancer: non-isocentric cyberknife versus isocentric RapidArc . Phys Med. 2014;30(6):654–661.
   PubMed Web of Science ®Google Scholar
• Macdougall ND, Dean C, Muirhead R. Stereotactic body radiotherapy in prostate cancer: is Rapidarc a better solution than cyberknife? Clin Oncol. 2014;26(1):4–9.
   Web of Science ®Google Scholar
• Scobioala S, Kittel C, Elsayad K, et al. A treatment planning study comparing IMRT techniques and cyber knife for stereotactic body radiotherapy of low-risk prostate carcinoma. Radiation Oncol. 2019;14:143.
   PubMed Web of Science ®Google Scholar
• Dang A, Kupelian PA, Cao M, et al. Image-guided radiotherapy for prostate cancer. Transl Androl Urol. 2018;7(3):308–320.
   PubMed Web of Science ®Google Scholar
• Quan EM, Li X, Li Y, et al. A comprehensive comparison of IMRT and VMAT plan quality for prostate cancer treatment. Int J Radiat Oncol Biol Phys. 2012;83(4):1169–1178.
   PubMed Web of Science ®Google Scholar
• Paluska P, Hanus J, Sefrova J, et al. Utilization of cone beam CT for reconstruction of dose distribution delivered in image-guidedradiotherapyofprostatecarcinoma—bonylandmarksetupcompared to fiducial markers setup. J Appl Clin Med Phys. 2013;14:4203.
   PubMed Web of Science ®Google Scholar
• Zelefsky MJ, Kollmeier M, Cox B, et al. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer. Int J Radiat Oncol Biol Phys. 2012;84:125–129.
   PubMed Web of Science ®Google Scholar
• Sveistrup J, afRosenschöld PM, Deasy JO, et al. Improvement in toxicity in high risk prostate cancer patients treated with image-guided intensity-modulated radiotherapy compared to 3D conformal radiotherapy without daily image guidance. Radiat Oncol. 2014;9:44.
   PubMed Web of Science ®Google Scholar
• Hamstra DA, Mariados N, Sylvester J, et al. Continued benefit to rectal separation for prostate radiation therapy: final results of a phase III trial. Int J Radiat Oncol Biol Phys. 2017;97:976–985.
   PubMed Web of Science ®Google Scholar
• Forero D, Dendukuri N, Almeida N. Hydrogel spacer to reduce rectal toxicity in prostate cancer radiotherapy: a health technology assessment. (Report No. 82). Montreal (QC): Technology Assessment Unit (TAU) of the McGill University Health Centre (MUHC); 2018.
   Google Scholar
• Mohler JL, Antonarakis ES, Armstrong AJ, et al. Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2019;17:479–505.
   PubMed Web of Science ®Google Scholar
• Michalski JM, Lawton C, El Naqa I, et al. Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2010;76(2):361–368.
   PubMed Web of Science ®Google Scholar
• Alongi F, Mazzola R, Fiorentino A, et al. Phase II study of accelerated Linac-based SBRT in five consecutive fractions for localized prostate cancer. Strahlenther Onkol. 2019;195(2):113–120.
   PubMed Web of Science ®Google Scholar
• Payne H, Mason M. Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer. 2011;105(11):1628–1634.
   PubMed Web of Science ®Google Scholar
• Thompson A, Keyes M, Pickles T, et al. Evaluating the phoenix definition of biochemical failure after 125I prostate brachytherapy: can PSA kinetics distinguish PSA failures from PSA bounces? Int J Radiation Oncol Biol Physics. 2010;78(2):415–421.
   PubMed Web of Science ®Google Scholar
• Atkinson TM, Ryan SJ, Bennett AV, et al. The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer. 2016;24(8):3669–3676.
   PubMed Web of Science ®Google Scholar
• Musunuru HB, Quon H, Davidson M, et al. Dose-escalation of five-fraction SABR in prostate cancer: toxicity comparison of two prospective trials. Radiother Oncol. 2016;118(1):112–117.
   PubMed Web of Science ®Google Scholar
• Loblaw A, Pickles T, Crook J, et al. Stereotactic ablative radiotherapy versus low dose rate brachytherapy or external beam radiotherapy: propensity score matched analyses of Canadian data. Clin Oncol. 2017;29(3):161–170.
   Web of Science ®Google Scholar
• Widmark A, Gunnlaugsson A, Beckman L, et al. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet. 2019;394(10196):385–395.
   PubMed Web of Science ®Google Scholar
• Jackson WC, Silva J, Hartman H, et al. Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies. Int J Radiat Oncol Biol Phys. 2019;104(4):778–789.
   PubMed Web of Science ®Google Scholar
• Menkarios C, Vigneault E, Brochet N, et al. Toxicity report of once weekly radiation therapy for low-risk prostate adenocarcinoma: preliminary results of a phase I/II trial. Radiat Oncol. 2011;6(1):112.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Taussky D, Menkarios C, et al. Prospective phase ii trial of once-weekly hypofractionated radiation therapy for low-risk adenocarcinoma of the prostate: late toxicities and outcomes. Clin Oncol (R Coll Radiol). 2016 ;28(6):386–392. Jun
   PubMed Web of Science ®Google Scholar
• Katz A, Formenti SC, Kang J. Predicting biochemical disease-free survival after prostate stereotactic body radiotherapy: risk-stratification and patterns of failure. Front Oncol. 2016;6:168.
   PubMed Web of Science ®Google Scholar
• Katz AJ, Santoro M, Ashley R, et al. Stereotactic body radiotherapy for organ-confined prostate cancer. BMC Urol. 2010;10:1.
   PubMed Web of Science ®Google Scholar
• Franzese C, Badalamenti M, Di Brina L, et al. Linac-based Stereotactic Body Radiation Therapy for Low and Intermediate-Risk Prostate cancer: long-term results and factors predictive for outcome and toxicity. Strahlenther Onkol. 2020;196(7):608–616.
   PubMed Web of Science ®Google Scholar